Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Radiotherapy and Immunotherapy for Cancer: From Systemic to Multisite
Ainhoa Arina et al.
CLINICAL CANCER RESEARCH (2020)
Priming and Propagating Anti-tumor Immunity: Focal Hypofractionated Radiation for in Situ Vaccination and Systemic Targeted Radionuclide Theranostics for Immunomodulation of Tumor Microenvironments
Justin C. Jagodinsky et al.
SEMINARS IN RADIATION ONCOLOGY (2020)
203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer
Mengshi Li et al.
CURRENT MEDICINAL CHEMISTRY (2020)
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Sanjeevani Arora et al.
ADVANCES IN THERAPY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Time to abandon single-site irradiation for inducing abscopal effects
Eric D. Brooks et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
Jason J. Luke et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy
Dongyoul Lee et al.
RADIATION RESEARCH (2018)
Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites
Zachary S. Morris et al.
CANCER IMMUNOLOGY RESEARCH (2018)
The 46th David A. Karnofsky Memorial Award Lecture: OligometastasisFrom Conception to Treatment
Ralph R. Weichselbaum
JOURNAL OF CLINICAL ONCOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Inhibiting the CD8+ T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radioresistance
Hai-yan Chen et al.
SCIENTIFIC REPORTS (2018)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model
Jake Wang et al.
PIGMENT CELL & MELANOMA RESEARCH (2017)
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box et al.
NATURE COMMUNICATIONS (2017)
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma
Amy Barone et al.
CLINICAL CANCER RESEARCH (2017)
Automated cassette-based production of high specific activity [203/212pb] peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer
Mengshi Li et al.
APPLIED RADIATION AND ISOTOPES (2017)
FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma
Julia A. Beaver et al.
CLINICAL CANCER RESEARCH (2017)
US FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
Maitreyee Hazarika et al.
CLINICAL CANCER RESEARCH (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Targeted Radionuclide Therapy of Human Tumors
Sergey V. Gudkov et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Systematic review of case reports on the abscopal effect
Yazan Abuodeh et al.
CURRENT PROBLEMS IN CANCER (2016)
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
Chrisann Kyi et al.
IMMUNOTHERAPY (2016)
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Michael B. Bernstein et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine
Ho Sze Chan et al.
EJNMMI RESEARCH (2016)
Current clinical trials testing the combination of immunotherapy with radiotherapy
Josephine Kang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization
Patrick Maier et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Innate and Adoptive Immune Cells Contribute to Natural Resistance to Systemic Metastasis of B16 Melanoma
Channakeshava Sokke Umeshappa et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2015)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi et al.
LANCET ONCOLOGY (2015)
Radiotherapy and Immunogenic Cell Death
Encouse B. Golden et al.
SEMINARS IN RADIATION ONCOLOGY (2015)
Current Clinical Trials Testing Combinations of Immunotherapy and Radiation
Mario Crittenden et al.
SEMINARS IN RADIATION ONCOLOGY (2015)
FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
Geoffrey Kim et al.
CLINICAL CANCER RESEARCH (2014)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Liufu Deng et al.
IMMUNITY (2014)
Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy
Udo S. Gaipl et al.
IMMUNOTHERAPY (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
Sofia R. Gameiro et al.
ONCOTARGET (2014)
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
Encouse B. Golden et al.
ONCOIMMUNOLOGY (2014)
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp et al.
ONCOIMMUNOLOGY (2014)
Radiation and immunotherapy: a synergistic combination
Anusha Kalbasi et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Targeted Radionuclide Therapy - An Overview
Ashutosh Dash et al.
CURRENT RADIOPHARMACEUTICALS (2013)
The convergence of radiation and immunogenic cell death signaling pathways
Encouse B. Golden et al.
FRONTIERS IN ONCOLOGY (2012)
Differential Effects of Alpha-Particle Radiation and X-Irradiation on Genes Associated with Apoptosis
Vinita Chauhan et al.
RADIOLOGY RESEARCH AND PRACTICE (2011)
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
George Sgouros et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Links between Innate Immunity and Normal Tissue Radiobiology
Doerthe Schaue et al.
RADIATION RESEARCH (2010)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
ME Keir et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
α-Melanocyte-stimulating hormone suppresses antigen-induced lymphocyte independently of melanocortin proliferation in humans 1 receptor gene status
A Cooper et al.
JOURNAL OF IMMUNOLOGY (2005)
Melanoma therapy via peptide-targeted α-radiation
YB Miao et al.
CLINICAL CANCER RESEARCH (2005)
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor
AA Lugade et al.
JOURNAL OF IMMUNOLOGY (2005)
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes
CT Garnett et al.
CANCER RESEARCH (2004)
Human melanocortin 1 receptor (MC1R) gene variants alter melanoma cell growth and adhesion to extracellular matrix
SJ Robinson et al.
ONCOGENE (2002)
Tissue distribution and differential expression of melanocortin I receptor, a malignant melanoma marker
F Salazar-Onfray et al.
BRITISH JOURNAL OF CANCER (2002)
Share Paper
